Co-infection with HIV and hepatitis C virus (HCV) is relatively common because of shared routes of transmission.
Researchers enrolled 50 co-infected people with severe liver injury (cirrhosis) and assigned them to receive 12 weeks of ledipasvir + sofosbuvir.
Participants were divided into two groups based on their use (or not) of anti-HIV therapy (commonly called ART or HAART):
The average profile of participants at the start of the study was as follows:
Anti-HIV drugs that were allowed in this clinical trial included the following:
Among all participants who were not using ART, 100% (13 of 13) achieved an SVR12.
Among ART users, 97% (36 of 37) achieved an SVR12.
There were no significant changes to CD4+ cell counts or HIV viral load or toxicities to major organ-systems.
No deaths or premature departures from the study occurred.
A larger study code-named ION-4 is ongoing in co-infected people. This trial has enrolled 335 participants with HCV genotypes 1 or 4, all of whom are using one of the following ART regimens:
ION-4 has enrolled participants from Canada, New Zealand and the U.S. Results are expected later in 2015 or early in 2016.
Townsend KS, Osinusi A, Nelson AK, et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: Results from the NIAID Eradicate trial. In: Program and abstracts of The Liver Meeting, 7-11 November 2014. Abstract 84.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|